Document is current
Any future updates will be listed below
-
Authors
Blas, Leandro
Shiota, Masaki https://orcid.org/0000-0002-3306-4858
Matsuyama, Hideyasu
Kamoto, Toshiyuki
Enokida, Hideki
Fujimoto, Naohiro
Sakai, Hideki
Igawa, Tsukasa
Kamba, Tomomi
Yokomizo, Akira
Naito, Seiji
Eto, Masatoshi
- License Information
-
More Information
Article History
Received: 21 May 2024
Accepted: 6 October 2024
First Online: 29 October 2024
Declarations
:
: MS (Janssen Pharmaceutical K.K., AstraZeneca, Astellas Pharma Inc.), HM (Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd.), TK (AstraZeneca, Merck Biopharma Co., Ltd.), HE (Astellas Pharma Inc.), TI (Astellas Pharma Inc., Janssen Pharmaceutical K.K.), AY (Astellas Pharma Inc., Janssen Pharmaceutical K.K.), ME (Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Bristol-Myers Squibb Co., Janssen Pharmaceutical K.K., MSD K.K., Merck Biopharma Co., Ltd., AstraZeneca, Eisai Co., Ltd.), have lecture fees, honoraria, or other fees from each entity. MS (Daiichi Sankyo Co., Ltd.), HM (Janssen Pharmaceutical K.K.), TK (Janssen Pharmaceutical K.K., Shin Nippon Biomedical Laboratories, Ltd., Ono Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd.), ME (Bristol-Myers Squibb Co., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., MSD K.K.) have research funds from each entity. ME (Sanofi K.K., Bayer Yakuhin, Astellas Pharma Inc, Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd.), HideM (Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd.) have scholarship (incentive) endowments or research grants from each entity. LB, NF, HS and SN have no COI to disclose.
: This study was approved by the central Institutional Review Board (14-E02). The study was performed in accordance with the Declaration of Helsinki.
: UMIN000014243.
: A written informed consent was obtained from each participant.
